Press Releases

Press Releases

November 19, 2021
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif. , Nov. 19, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that on November 18, 2021 (the “Date of Grant”), the Company approved the grant of inducement
November 13, 2021
Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Cancers at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Tumor Infiltrating Lymphocyte (TIL) Cell Therapy   in Combination with Pembrolizumab in Immune-Checkpoint Inhibitor Naïve Patients Shows Overall Response Rate (ORR) of 57% in Cervical Cancer, 60% in Melanoma with 30% Complete Response (CR) and 39% in Head and Neck Cancer SITC Update Conference Call
November 12, 2021
Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer at Society for Immunotherapy of Cancer (SITC) Annual Meeting
21.4% Overall Response Rate (ORR) in Heavily Pre-Treated Patients with Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer (mNSCLC) Conference Call and Webcast on Saturday, November 13 at 5:30pm ET SAN CARLOS, Calif. , and WASHINGTON , Nov. 12, 2021 (GLOBE NEWSWIRE) -- Iovance
November 09, 2021
Iovance Biotherapeutics Announces Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Cell Therapy in Multiple Solid Tumors at Society for Immunotherapy of Cancer (SITC) Annual Meeting
TIL in Combination with Pembrolizumab Increases Overall Responses in Immune-Checkpoint Inhibitor-Naïve Cervical Cancer, Melanoma, and Head and Neck Cancer 21.4% Overall Response Rate (ORR) for TIL Therapy in Advanced, Immune Checkpoint  Inhibitor-Treated Non-Small Cell Lung Cancer (NSCLC) SAN
November 08, 2021
Iovance Biotherapeutics to Present at Upcoming Conferences
SAN CARLOS, Calif. , Nov. 08, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following conferences in November: Festival of
November 04, 2021
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2021 Financial Results and Corporate Updates
Advancing TIL Platform in Multiple Solid Tumors and Treatment Settings SAN CARLOS, Calif. , Nov. 04, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL,
October 25, 2021
Iovance Biotherapeutics to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 4, 2021
SAN CARLOS, Calif. , Oct. 25, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its third quarter financial results on Thursday, November 4, 2021 .
October 18, 2021
Iovance Biotherapeutics to Host Conference Call and Webcast to Highlight Data at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Oral Presentation of Clinical Data for TIL in Combination with Pembrolizumab in Immune-Checkpoint Inhibitor Naïve Patients with Advanced Cancers Poster for TIL Therapy in Advanced, Immune Checkpoint Inhibitor-Treated Non-Small Cell Lung Cancer (NSCLC) SAN CARLOS, Calif. , Oct.
October 01, 2021
Iovance Biotherapeutics to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Cell Therapies Across Multiple Solid Tumors and Treatment Settings at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
Oral Presentation of Clinical Data for TIL in Combination with Pembrolizumab  in Immune Checkpoint Inhibitor-Naïve Patients with Advanced Cancers Poster for LN-145 Monotherapy in Advanced, Immune Checkpoint  Inhibitor-Treated Non-Small Cell Lung Cancer (NSCLC) Additional Posters Highlight Potential
September 28, 2021
Iovance Biotherapeutics Celebrates Grand Opening of Iovance Cell Therapy Center (iCTC) in the Philadelphia Navy Yard
Ribbon Cutting to be Led by Patient Advocacy Organizations, Caregivers, and Key Stakeholders Largest and First Centralized, Scalable, State-of-the-Art Facility with the Potential to Manufacture TIL Cell Therapies for Thousands of Cancer Patients Annually SAN CARLOS, Calif. , Sept.
September 23, 2021
Iovance Biotherapeutics Initiates Clinical Supply of Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy Manufactured at Iovance Cell Therapy Center (iCTC)
First Patient Infused with TIL Cell Therapy Manufactured at iCTC SAN CARLOS, Calif. , Sept. 23, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and
August 05, 2021
Iovance Biotherapeutics Reports Second Quarter and First Half 2021 Financial Results and Corporate Updates
Expanding Leadership for TIL Cell Therapy in Solid Tumors SAN CARLOS, Calif. , Aug. 05, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and
July 19, 2021
Iovance Biotherapeutics to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 5, 2021
SAN CARLOS, Calif. , July 19, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its second quarter financial results on Thursday, August 5, 2021 .
June 29, 2021
Iovance Biotherapeutics to Host Conference Call and Webcast to Discuss Clinical Data for LN-145 in Non-Small Cell Lung Cancer on June 29, 2021 at 4:30pm ET
SAN CARLOS, Calif. , June 29, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that Management will host a conference call and live audio webcast to discuss the recent clinical
June 29, 2021
Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer
21.4% Overall Response Rate (ORR) in Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer (mNSCLC) Patients Following One or More Prior Systemic Therapies   Including Immunotherapy First Patient Dosed in Registration-Supporting IOV-LUN-202 Study in Second Line mNSCLC SAN CARLOS, Calif.
June 06, 2021
Iovance Biotherapeutics Announces 33-Month Follow Up Data for Lifileucel in Advanced Melanoma at ASCO 2021 Annual Meeting
Median Duration of Response (DOR) Not Reached at 33.1 Months  of Median Study Follow Up in Cohort 2 in C-144-01 Study Early Intervention with Lifileucel Following Progression on Anti-PD-1 Therapy May Maximize Benefit ASCO Update Conference Call and Webcast at 12 p.m. ET Today SAN CARLOS, Calif.
June 04, 2021
Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Melanoma at ASCO 2021 Annual Meeting
86% Overall Response Rate (ORR) and 43% Complete Response Rate in Immune Checkpoint Inhibitor (ICI) Naïve Advanced Melanoma Patients in IOV-COM-202 Clinical Study Initial 7 Patients Show 3 Complete Responses, 3 Partial Responses and 1 Best Response of Stable Disease ASCO Update Conference Call and
June 01, 2021
Iovance Biotherapeutics to Present at Upcoming Conferences
SAN CARLOS, Calif. , June 01, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following virtual conferences in June:
May 19, 2021
Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma at Upcoming ASCO 2021 Annual Meeting
86% Overall Response Rate (ORR) for Lifileucel in Combination with Pembrolizumab in Immune Checkpoint Inhibitor (ICI) Naïve Advanced Melanoma Patients in IOV-COM-202 Clinical Study At Median of 28-Month Study Follow up, Median Duration of Response (DOR) not reached in Cohort 2 in post-PD1 Advanced
May 18, 2021
Iovance Biotherapeutics Provides Regulatory Update for Lifileucel Potency Assays
SAN CARLOS, Calif. , May 18, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced receipt of regulatory feedback from the U.S. Food and Drug Administration (FDA) regarding its
May 12, 2021
Journal of Clinical Oncology Publishes Clinical Data for Cohort 2 in Iovance C-144-01 Study of Lifileucel TIL Therapy in Metastatic Melanoma
Median Duration of Response Not Reached at 18.7 Months of Median Study Follow Up C-144-01 Study Contributes to Advancement in TIL Therapy Using Centrally  Standardized Manufacturing, Allowing for Broadened Patient Access SAN CARLOS, Calif. , May 12, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics,
May 06, 2021
Iovance Biotherapeutics Reports First Quarter 2021 Financial Results and Corporate Updates
Expanding First-in-Class TIL Cell Therapy Platform for Solid Tumors SAN CARLOS, Calif. , May 06, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and
May 04, 2021
Iovance Biotherapeutics to Present at Upcoming Conferences
SAN CARLOS, Calif. , May 04, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following virtual conferences in May: Truist
April 28, 2021
Iovance Biotherapeutics to Present Clinical Data for Lifileucel in Advanced Melanoma at ASCO 2021 Annual Meeting
Updated Lifileucel Data from Cohort 2 in C-144-01 Clinical Study Initial Data for Lifileucel in Combination with Pembrolizumab in Immune Checkpoint Inhibitor Naïve Advanced Melanoma Cohort 1A in IOV-COM-202 Clinical Study SAN CARLOS, Calif. , April 28, 2021 (GLOBE NEWSWIRE) -- Iovance
April 27, 2021
Iovance Biotherapeutics to Host First Quarter Financial Results Conference Call and Webcast on Thursday, May 6, 2021
SAN CARLOS, Calif. , April 27, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its first quarter financial results on Thursday, May 6, 2021 .
April 09, 2021
Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma During American Association for Cancer Research (AACR) 2021 Annual Meeting
Median Duration of Response Not Reached at 28.1 Months  of Median Study Follow Up in Cohort 2 of C-144-01 Study 36.4% Overall Response Rate; Continued Deepening of Responses SAN CARLOS, Calif. , April 09, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc.
March 15, 2021
Iovance Biotherapeutics Appoints Igor Bilinsky as Chief Operating Officer
SAN CARLOS, Calif. , March 15, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced the appointment of Igor Bilinsky , Ph.D., as Chief Operating Officer, effective today. Dr.
March 10, 2021
Iovance Biotherapeutics to Present Updated Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel in Advanced Melanoma at American Association for Cancer Research (AACR) 2021 Annual Meeting
SAN CARLOS, Calif. , March 10, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that long-term interim data from Cohort 2 in the C-144-01 clinical study (NCT02360579) in
March 01, 2021
Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences
SAN CARLOS, Calif. , March 01, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following virtual healthcare conferences:
February 25, 2021
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Updates
Advancing First-in-Class TIL Cell Therapy for Solid Tumors SAN CARLOS, Calif. , Feb. 25, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and
February 18, 2021
Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, February 25, 2021
SAN CARLOS, Calif. , Feb. 18, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its fourth quarter and full year 2020 financial results on Thursday, February 25, 2021 .
January 19, 2021
Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences
SAN CARLOS, Calif. , Jan. 19, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following virtual healthcare conferences: B.